Literature DB >> 2919590

Detection of human immunodeficiency virus-1 by 35S-RNA in situ hybridization in solitary esophageal ulcers in two patients with the acquired immune deficiency syndrome.

D P Kotler1, C S Wilson, G Haroutiounian, C H Fox.   

Abstract

Esophageal disease frequently complicates the course of the acquire immune deficiency syndrome. In two patients with unusual refractory esophageal ulcers, we were able to demonstrate the presence of human immunodeficiency virus RNA in lymphocytes and mononuclear cells from the ulcer base, using an in situ hybridization technique. These observations suggest that human immunodeficiency virus may play a role in the development or persistence of solitary refractory esophageal ulcers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919590

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.

Authors:  S M Naum; P J Molloy; R J Kania; J McGarr; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

2.  Advantages and pitfalls of the polymerase chain reaction in the diagnosis of esophageal ulcers in AIDS patients.

Authors:  Marcos Carvalho Borges; Jeová Keny Baima Colares; Danielle Malta Lima; Benedito Antônio Lopes Fonseca
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

3.  Idiopathic esophageal ulceration in the acquired immunodeficiency syndrome: radiologic reappraisal in 10 patients.

Authors:  D Frager; D P Kotler; J Baer
Journal:  Abdom Imaging       Date:  1994 Jan-Feb

Review 4.  HIV enteropathy--a challenge in diagnosis and management.

Authors:  S J Antony
Journal:  J Natl Med Assoc       Date:  1994-05       Impact factor: 1.798

5.  Quantitative analysis of mononuclear cells expressing human immunodeficiency virus type 1 RNA in esophageal mucosa.

Authors:  P D Smith; C H Fox; H Masur; H S Winter; D W Alling
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.